Page last updated: 2024-09-04

desacetyl cephapirin and Obesity

desacetyl cephapirin has been researched along with Obesity in 1 studies

*Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY). [MeSH]

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alcaro, S; Ambrosio, FA; Artese, A; Bagetta, D; Carta, F; Catalano, R; Costa, G; Lupia, A; Maruca, A; Moraca, F; Ortuso, F; Rocca, R; Romeo, I; Supuran, CT; Vullo, D1

Other Studies

1 other study(ies) available for desacetyl cephapirin and Obesity

ArticleYear
A computer-assisted discovery of novel potential anti-obesity compounds as selective carbonic anhydrase VA inhibitors.
    European journal of medicinal chemistry, 2019, Nov-01, Volume: 181

    Topics: Anti-Obesity Agents; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Computer-Aided Design; Drug Discovery; Drug Repositioning; Humans; Molecular Docking Simulation; Obesity

2019